La cadena de opciones muestra datos clave de las opciones de acciones de CalciMedica a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para CalciMedica..

CalciMedica (NASDAQ:CALC) Bolsa, Cadena de Opciones

CalciMedica

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.

CalciMedica Inc

Calcitech Ltd

Calcol Inc

Daiwa Capital analyst Dennis Ip upgrades GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) from Outperform to Buy and raises the price target from $245 to $336.

News

Upgrades

Price Target

Analyst Ratings

Daiwa Capital Upgrades GE Vernova to Buy, Raises Price Target to $336

WIIM

VF Corp shares are trading higher after the company announced financial targets at its investor day event.

GPRO

GoPro shares are trading lower. The company announced it approved a restructuring plan which includes a 26% workforce reduction.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health shares are trading lower in possible reaction to Ozempic and Wegovy being listed as available by the FDA.

Enovix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) shares are trading higher Wednesday following the company's better-than-expected third-quarter results. Enovix also announced a new development agreement with a leading smartphone OEM. Here&#8217;s what <a href="https://www.benzinga.com/news/earnings/24/10/41613274/enovix-stock-is-surging-after-the-bell-whats-going-on">you need to know.</a>
The Details: For the third quarter, Enovix reported revenue of $4.32 million, above estimates of $4.11 million. The company posted a loss of 17 cents per share, beating the estimated loss of 20 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Enovix CEO Raj Talluri highlighted the company&#8217;s progress, noting that Fab2 is now operational and shipping customer samples. The company&#8217;s key goals for the rest of 2024 include completing SAT for its High-Volume Line and delivering EX-2M samples.
For the fourth quarter, Enovix expects revenue between $8 million and $10 million, versus estimates of $7.38 million. The company expects an adjusted loss per share of 15 to 21 cents.
What Else: In addition to the quarterly results, Enovix announced a development agreement with "one of the leading global smartphone OEMs with top five market share in China."
Enovix said it will develop a fully active silicon anode battery tailored for specific smartphone models under the new agreement, targeting a launch in the fourth quarter of 2025. Enovix said the agreement marks the company&#8217;s second deal with leading smartphone OEMs.
"The company now has agreements with two of the leading smartphone OEMs and has further sales momentum building in IoT and EV markets," the company said.
Benchmark analyst Michael Legg reiterated Enovix with a Buy and maintained a price target of $25 on Wednesday. Cantor Fitzgerald analyst Derek Soderberg reiterated an <a href="https://www.benzinga.com/analyst-stock-ratings">Overweight rating</a> and price target of $30.
ENVX Price Action: Enovix shares were up 5.41% at $11.21 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga pro.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41633104/alphabet-to-rally-around-33-here-are-10-top-analyst-forecasts-for-wednesday">Alphabet To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>
Image Via Shutterstock.

Earnings

Global

Movers

ENVX

What's Going On With Enovix Stock Today?

BTIG analyst Carl Reichardt maintains D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) with a Buy and lowers the price target from $190 to $186.

BTIG Maintains Buy on D.R. Horton, Lowers Price Target to $186

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) will likely highlight the performance of its iPhone 16 and upcoming product releases when the company reports fourth-quarter financial results <a href="https://www.benzinga.com/earnings">after market close Thursday. </a>
Earnings Estimates: Analysts expect the Cupertino, California-based company to report fourth-quarter revenue of $94.56 billion, up from $89.5 billion in last year's fourth quarter, according to data <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103024&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
Apple has beaten analyst estimates for revenue in six straight quarters and nine of the last 10 quarters overall.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/10/41591063/apple-will-be-the-first-to-hit-4-trillion-market-cap-milestone-says-dan-ives-as-hundreds-of-apps">Apple &#8216;Will Be The First To Hit&#8217; $4 Trillion Market Cap Milestone, Says Dan Ives As Hundreds Of Apps Will Be Built On AI Feature</a>
Analysts expect the company to report fourth-quarter earnings per share of $1.53, up from $1.46 reported in last year's fourth quarter. The company has beaten analyst estimates for earnings per share in six straight quarters and nine of the last 10 quarters overall.
What Analysts Are Saying: The iPhone 16 will be one of the key items analysts are watching in the earnings report and conference call.
"iPhone 16 demand has been relatively stable year-over-year and better-than-feared given more cautious data points around shorter lead-times relative to year-ago and production cuts," Goldman Sachs analyst Michael Ng <a href="https://www.benzinga.com/news/earnings/24/10/41554508/apple-q4-earnings-preview-goldman-sachs-analyst-anticipates-big-earnings-beat-resilient-iphone-16-d">recently said.</a>
Ng reiterated a Buy rating on Apple with a $275 price target recently.
The analyst said Apple's push into artificial intelligence with Apple Intelligence could be a "long-term demand driver."
Another area Ng will be watching closely in Apple's report is the company's Services segment, which could be underestimated by investors.
"Apple&#8217;s installed base growth, secular growth in services, and new product innovation should more than offset cyclical headwinds to product revenue, such as a reduced iPhone unit demand due to a lengthening replacement cycle and reduced consumer demand for the PC &amp; tablet category."
Lower lead times for the iPhone 16 could signal a lack of demand for the newest version of the popular Apple smartphone, Morgan Stanley analyst Erik Woodring<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41350919/apple-analyst-predicts-a-september-quarter-revenue-beat-allays-fears-over-shorter-i"> recently said.</a>
The analyst, who has an Overweight rating and $273 price target on Apple, said while the data for lead times was bad for the iPhone 16, it could be better than the previous iPhone 15.
Lower lead times could also be a factor of Apple being more proactive with its suppliers in keeping inventory in check to avoid supply constraints, Woodring said.
"We believe that better supply conditions are one of the contributing factors to why iPhone lead times are shorter this cycle than in recent cycles," Woodring said.
Here are other recent<a href="https://www.benzinga.com/quote/AAPL/analyst-ratings"> analyst ratings on Apple </a>and their price targets:
<ul>
<li>KeyBanc: Downgraded from Sector-weight to Underweight with $200 price target</li>
<li>Piper Sandler: Reiterated Neutral rating with $225 price target</li>
<li>Bank of America: Reiterated Buy rating with $256 price target</li>
<li>Barclays: Maintained Underweight rating with $186 price target</li>
</ul>
Key Items to Watch: All eyes will be on the iPhone 16 when Apple reports fourth-quarter results Thursday.
Other items that investors will be watching include Services, the initial rollout of Apple Intelligence and China.
<ul>
<li>Services hit an<a href="https://www.benzinga.com/news/earnings/24/08/40116376/apple-q3-earnings-beat-expectations-tim-cook-highlights-breakthrough-ai-platform-installed-base-of-"> all-time record</a> for revenue in the third quarter but came in below Street estimates.</li>
<li>Weakness in China for the third quarter contributed to shares seeing downward pressure after the earnings results.</li>
<li>Apple&#8217;s recent <a href="https://www.benzinga.com/news/24/10/41582312/apples-introduces-imac-m4-chip-brings-faster-speeds-and-smarter-ai-features">AI product announcements</a> could be highlighted in the results as future catalysts.</li>
</ul>
Price Action: Apple stock is down 1% to $230.38 on Wednesday versus a 52-week trading range of $164.08 to $237.49. Apple stock is up 24% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/success-stories/24/10/41441641/apple-ceo-tim-cook-says-apple-intelligence-will-make-products-profoundly-different-new-ai-technol">Apple CEO Tim Cook Says New AI Technology Will Get Consumers &#8216;On A Different Technology Curve&#8217;</a></li>
</ul>
Image:

Analyst Color

Previews

Reiteration

Tech

Trading Ideas

AAPL

Apple Q4 Earnings Preview: All Eyes On iPhone 16 Demand, Can Tech Giant Beat Analyst Estimates 7 Quarters Straight?

Deep-pocketed investors have adopted a bearish approach towards Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MU usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 36 extraordinary options activities for Micron Technology. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 27% leaning bullish and 66% bearish. Among these notable options, 8 are puts, totaling $386,191, and 28 are calls, amounting to $1,631,443.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $80.0 to $250.0 for Micron Technology during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Micron Technology's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Micron Technology's whale trades within a strike price range from $80.0 to $250.0 in the last 30 days. 
<h3>Micron Technology 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730315756_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.1</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$120.00</td>
<td>$287.5K</td>
<td>11.2K</td>
<td style="text-align: right;">711</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$6.15</td>
<td>$5.85</td>
<td>$5.85</td>
<td>$250.00</td>
<td>$117.0K</td>
<td>331</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/01/24</td>
<td>$11.5</td>
<td>$10.45</td>
<td>$10.55</td>
<td>$96.00</td>
<td>$105.5K</td>
<td>336</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/01/24</td>
<td>$9.75</td>
<td>$9.6</td>
<td>$9.68</td>
<td>$96.00</td>
<td>$97.4K</td>
<td>336</td>
<td style="text-align: right;">302</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/01/24</td>
<td>$9.7</td>
<td>$9.45</td>
<td>$9.53</td>
<td>$96.00</td>
<td>$95.2K</td>
<td>336</td>
<td style="text-align: right;">100</td>
</tr>
</tbody>
</table>

<h3>About Micron Technology</h3>
Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.
Having examined the options trading patterns of Micron Technology, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Micron Technology's Current Market Status</h3>
<ul>
<li>Trading volume stands at 9,339,049, with MU's price down by -3.16%, positioned at $104.76.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 49 days.</li>
</ul>
<h3>What Analysts Are Saying About Micron Technology</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $142.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Micron Technology with a target price of $135. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $150. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Micron Technology with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Looking At Micron Technology's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MCK, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 20 uncommon options trades for McKesson.
This isn't normal.
The overall sentiment of these big-money traders is split between 65% bullish and 35%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $538,721, and 12 are calls, for a total amount of $842,156.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $450.0 to $520.0 for McKesson during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for McKesson options trades today is 166.17 with a total volume of 3,049.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for McKesson's big money trades within a strike price range of $450.0 to $520.0 over the last 30 days.
<h3>McKesson Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730315752_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$13.8</td>
<td>$11.2</td>
<td>$11.2</td>
<td>$510.00</td>
<td>$253.1K</td>
<td style="text-align: right;">763</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$12.8</td>
<td>$12.0</td>
<td>$12.7</td>
<td>$507.50</td>
<td>$158.8K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">125</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$15.8</td>
<td>$14.8</td>
<td>$14.8</td>
<td>$450.00</td>
<td>$106.5K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">72</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$15.9</td>
<td>$12.9</td>
<td>$14.7</td>
<td>$450.00</td>
<td>$94.0K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">136</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$15.7</td>
<td>$14.3</td>
<td>$14.6</td>
<td>$450.00</td>
<td>$87.6K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">196</td>
</tr>
</tbody>
</table>

<h3>About McKesson</h3>
McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
In light of the recent options history for McKesson, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of McKesson</h3>
<ul>
<li>Currently trading with a volume of 455,253, the MCK's price is up by 0.02%, now at $499.28. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 7 days.</li>
</ul>
<h3>What Analysts Are Saying About McKesson</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $630.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Leerink Partners persists with their Outperform rating on McKesson, maintaining a target price of $630. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for McKesson, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

What the Options Market Tells Us About McKesson

Deep-pocketed investors have adopted a bullish approach towards Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in C usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 24 extraordinary options activities for Citigroup. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 66% leaning bullish and 29% bearish. Among these notable options, 4 are puts, totaling $161,279, and 20 are calls, amounting to $842,708.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $75.0 for Citigroup over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Citigroup's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Citigroup's whale activity within a strike price range from $40.0 to $75.0 in the last 30 days. 
<h3>Citigroup 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730315747_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/17/26</td>
<td>$5.75</td>
<td>$5.5</td>
<td>$5.6</td>
<td>$75.00</td>
<td>$95.1K</td>
<td>5.7K</td>
<td>0</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.15</td>
<td>$8.05</td>
<td>$8.15</td>
<td>$65.00</td>
<td>$66.0K</td>
<td>3.7K</td>
<td>85</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.07</td>
<td>$2.04</td>
<td>$2.05</td>
<td>$64.00</td>
<td>$57.1K</td>
<td>5.3K</td>
<td>551</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/08/24</td>
<td>$1.06</td>
<td>$1.04</td>
<td>$1.06</td>
<td>$66.00</td>
<td>$53.4K</td>
<td>1.2K</td>
<td>568</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/01/24</td>
<td>$1.06</td>
<td>$1.02</td>
<td>$1.06</td>
<td>$64.00</td>
<td>$53.0K</td>
<td>9.3K</td>
<td>3.0K</td>
</tr>
</tbody>
</table>

<h3>About Citigroup</h3>
Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.
After a thorough review of the options trading surrounding Citigroup, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Citigroup's Current Market Status</h3>
<ul>
<li>With a volume of 5,650,616, the price of C is down -0.12% at $64.61. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 77 days.</li>
</ul>
<h3>What Analysts Are Saying About Citigroup</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $79.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Citigroup, targeting a price of $92. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Citigroup, which currently sits at a price target of $82. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Citigroup, which currently sits at a price target of $91. 
&#x2A; An analyst from Evercore ISI Group has decided to maintain their In-Line rating on Citigroup, which currently sits at a price target of $64. 
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Citigroup, which currently sits at a price target of $70. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Citigroup, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Market Whales and Their Recent Bets on Citigroup Options

Scotiabank analyst Mario Saric maintains Brookfield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BN#NYSE">BN</a>) with a Sector Outperform and raises the price target from $51.25 to $65.

Scotiabank Maintains Sector Outperform on Brookfield, Raises Price Target to $65

Mirion Technologies shares are trading higher after the company reported better-than-expected Q3 earnings and raised its FY24 sales guidance.

Scotiabank analyst Mario Saric maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Sector Outperform and raises the price target from $45.5 to $55.5.

Scotiabank Maintains Sector Outperform on Brookfield Asset Mgmt, Raises Price Target to $55.5

Scotiabank analyst Maher Yaghi maintains American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) with a Sector Outperform and lowers the price target from $248 to $236.

Scotiabank Maintains Sector Outperform on American Tower, Lowers Price Target to $236

On Tuesday, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41598312/novartis-q3-earnings-beats-expectations-on-strong-sales-from-key-drugs-lifts-2024-outlook" rel="noreferrer noopener">consensus of $12.76 billion</a>.
Guidance: Novartis also raised its 2024 full-year guidance again this year.
In a statement, Novartis said it expects full-year core operating income to grow by a &#8220;high teens&#8221; percentage, compared with previous guidance of a &#8220;mid-to-high teens&#8221; percentage.
Novartis forecasts full-year sales growth in the low double digits, having previously guided for high-single to low-double-digit growth.
Pelabresib filing was further delayed, triggering a $800 million impairment charge related to the $2.9 billion <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38497134/morphosys-says-novartis-deal-progressing-steadily-despite-safety-concerns-over-bone-marrow-cancer" rel="noreferrer noopener">acquisition of MorphoSys</a>.
Earlier this year, MorphoSys faced&nbsp;a burgeoning safety concern surrounding&nbsp;pelabresib.
Goldman Sachs notes that MorphoSys-related impairment charge is somewhat underwhelming, raising doubts about the company&#8217;s M&amp;A strategy.
Truist notes that Novartis is concentrating on preparing the market for the PSMAFore label, which is expected to triple its addressable market.
They also pointed out that growth opportunities in China and Japan, and metastatic hormone-sensitive prostate cancer (mHSPC) and oligometastatic disease, could push Pluvicto&#8217;s sales well above the projected $2 billion peak.
The company is committed to maximizing the potential of Pluvicto and its radioligand therapy (RLT) portfolio.
For other radiopharmaceutical companies targeting PSMA, entering this market may become more challenging.
A crucial question remains regarding the standards that must be met to compete with more effective radioligand products. This context relates to companies such as Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), which have RLT products in their pipelines, as well as smaller companies, including Y-mAbs Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) and Perspective Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NASDAQ">CATX</a>).
Novartis highlighted continued strong growth and momentum and sees room to grow the market size for B-cell inhibition in multiple sclerosis, relating Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
Truist highlights Novartis&#8217; strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few larger bolt-on acquisitions.
A Truist analyst indicated that they will be monitoring how the adoption of Leqvio may affect Amgen Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Repatha and Regeneron Pharmaceuticals Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Praluent. Meanwhile, Novartis has reported that the launch is advancing smoothly, and Leqvio continues to grow, outpacing the overall market as per the management.
Novartis&#8217; Cosentyx witnessed strong uptake and continued brand growth driven by hidradenitis suppurativa expansion, and the market opportunity can accommodate several players, Abbvie Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NASDAQ">ABBV</a>), Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), and Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>).
Price Action: NVS stock is down 0.48% at $110.00 at last check Wednesday.
Photo by Taljat David via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41629995/orthopedic-implant-maker-zimmer-biomet-reports-better-than-expected-q3-earnings-updates-annual-fore" target="_blank" rel="noreferrer noopener">Orthopedic Implant Maker Zimmer Biomet Reports Better-Than-Expected Q3 Earnings, Updates Annual Forecasts</a></li>
</ul>

Biotech

Equities

Large Cap

Health Care

General

ABBV

AMGN

BIIB

CATX

INCY

KYMR

REGN

YMAB

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

BTIG analyst Clark Lampen maintains Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Buy and raises the price target from $114 to $142.

BTIG Maintains Buy on Trade Desk, Raises Price Target to $142

BTIG analyst Ryan Zimmerman maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Buy and raises the price target from $383 to $394.

BTIG Maintains Buy on Stryker, Raises Price Target to $394

Scotiabank analyst Tomas Gonzalez maintains Enel Chile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENIC#NYSE">ENIC</a>) with a Sector Outperform and lowers the price target from $4.4 to $3.9.

ENIC

Scotiabank Maintains Sector Outperform on Enel Chile, Lowers Price Target to $3.9

On Wednesday,&nbsp;Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) released the results of the primary endpoint of the ACURATE IDE trial of&nbsp;ACURATE&nbsp;neo2 Aortic Valve System for patients with severe, symptomatic aortic stenosis at risk of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41629382/acurate-neo2-aortic-valve-system-data-presented-at-late-breaking-clinical-trial-session-at-tct-202" rel="noreferrer noopener">open-heart surgery</a>.
The data were presented at Transcatheter Cardiovascular Therapeutics 2024, the annual scientific symposium of the Cardiovascular Research Foundation.
This randomized trial evaluated the ACURATE&nbsp;neo2 valve, the company&#8217;s second-generation transcatheter aortic valve replacement (TAVR) technology, versus a pre-defined control valve, either the commercially available SAPIEN valve or the Evolut transcatheter aortic valve system.
SAPIEN valve is sold by Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), and Evolut is Medtronic Plc&#8217;s NYSE: MDT) brand.
The composite rate of all-cause mortality, stroke, or rehospitalization at one year was 16.16% in the ACURATE&nbsp;neo2 arm and 9.53% in the control arm, not meeting the prespecified criterion for non-inferiority (the posterior probability for non-inferiority was 77.9%, which is lower than the non-inferiority test threshold of 97.5%).
&#8220;This trial is the largest randomized comparison of TAVR platforms and was conducted over four years, including during a global pandemic that introduced complexities for enrollment,&#8221; said&nbsp;Michael Reardon, co-principal investigator of the ACURATE IDE trial.
The company also presented data from a post-hoc analysis to identify and evaluate expanded and under-expanded ACURATE&nbsp;neo2 valve frames within the ACURATE IDE trial.
The company reviewed key procedural factors, including pre-and post-dilation, which help prepare for, enable, and confirm proper valve expansion during the procedure.
Following this review, an assessment of implant quality for the ACURATE&nbsp;neo2 valve was initiated. The assessment highlighted that approximately 20% of the valves were under-expanded.
Data from the assessment also demonstrated that the rate of death, stroke, or rehospitalization at one year was similar between the ACURATE&nbsp;neo2 expanded group and the control group.
Boston Scientific continues to work closely with the U.S. Food and Drug Administration on the regulatory strategy for approval of the ACURATE valve platform in the U.S.
The ACURATE&nbsp;neo2 Aortic Valve System and the ACURATE Prime Aortic Valve System are approved in Europe.
In the&nbsp;U.S., the ACURATE&nbsp;neo2 Aortic Valve System and the ACURATE Prime Aortic Valve System are investigational devices.
Price Action: BSX stock is down 1.66% at $83.16 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41630458/cdw-shares-dip-as-q3-sales-miss-amid-weak-hardware-demand-and-customer-delays" target="_blank" rel="noreferrer noopener">CDW Shares Dip As Q3 Sales Miss Amid Weak Hardware Demand And Customer Delays</a></li>
</ul>

Why is Boston Scientific Stock Trading Lower On Wednesday?

BMEA

Biomea Fusion shares are trading lower. The company reported Q3 financial results.

CalciMedica announces positive topline data from phase 2b CARPO trial of Auxora

CalciMedica (CALC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H....

Buy Rating Affirmed on CalciMedica Amidst Promising Auxora Clinical Trial Results and Market Potential

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on CalciMedica (CALC – Research Report), with a price target o...

CalciMedica (CALC) Receives a Buy from Oppenheimer

CalciMedica to join Russell Microcap Index

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on CalciMedica (CALC – Research Report), retaining the price target of $20.00. ...

Buy Rating Affirmed for CalciMedica's Auxora Amid Promising AKI Treatment Prospects

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
CalciMedica (NASDAQ:<a href="https://investorplace.com/stock-quotes/calc-stock-quote/">CALC</a>) just reported results for the second quarter of 2024.<ul><li>CalciMedica reported earnings per share of -36 cents. This was above the analyst estimate for EPS of -52 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/calc-stock-earnings-calcimedica-for-q2-of-2024/">CALC Stock Earnings: CalciMedica Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CALC Stock Earnings: CalciMedica Beats EPS for Q2 2024

CalciMedica: Strong Q2 Financials and Promising Clinical Trials Underpin Buy Rating

CalciMedica GAAP EPS of -$0.36 beats by $0.22

Oppenheimer Sticks to Their Buy Rating for CalciMedica (CALC)

An announcement from CalciMedica (CALC) is now available. CalciMedica, Inc. stockholders convened for the 2024 Annual Meeting, endorsing a key amen...

CalciMedica Shareholders Back Expansion and Elect Directors

CALC

Press Releases

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica Set to Join Russell Microcap® Index

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Comments

CalciMedica

CalciMedica (CALC) Opciones

Loading...

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL